Bisphosphonates for osteoporosis prevention and treatment |
| |
Authors: | Courtney I Jarvis PharmD Anna K Morin PharmD Ann M Lynch RPh |
| |
Institution: | (1) Department of Pharmacy Practice, School of Pharmacy, Massachusetts College of Pharmacy and Health Sciences, 19 Forster Street, 01608 Worcester, MA |
| |
Abstract: | As potent inhibitors of bone resorption, bisphosphonates (BPs) have been used to treat a variety of disorders of calcium and
bone metabolism, including osteoporosis. Paget's disease, and metastatic bone disease. Numerous clinical studies have shown
BPs to be useful and cost-effective options for the prevention and treatment of fractures and bone loss associated with postmenopausal
osteoporosis, senile osteoporosis in men, and glucocorticoid-induced osteoporosis. With proper self-administration in patients
without underlying gastrointestinal (GI) disorders, oral bisphosphonates are usually safe, however, they can cause upper GI
irritation. The most common side effects are nausea, diarrhea, gastritis, and esophageal irritation Newer, longer-acting BPs
and parenteral administration have lead to options for patients who cannot tolerate oral BPs. |
| |
Keywords: | Bisphosphonates osteoporosis etidronate clodronate tiludronate alendronate pamidronate risedronate ibandronate zoledronic acid |
本文献已被 SpringerLink 等数据库收录! |
|